First American Bank Lowered Its Johnson & Johnson (JNJ) Position; Veeva Systems Has 1.06 Sentiment

First American Bank decreased Johnson & Johnson (JNJ) stake by 6.98% reported in 2017Q3 SEC filing. First American Bank sold 4,487 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The First American Bank holds 59,837 shares with $7.78M value, down from 64,324 last quarter. Johnson & Johnson now has $354.30 billion valuation. The stock increased 2.34% or $3.02 during the last trading session, reaching $132.06. About 6.42 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since March 9, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, and internationally. The company has market cap of $10.98 billion. The firm offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, which allow pharmaceutical and biotechnology companies to target and support sales and marketing to physicians, other healthcare professionals, and healthcare organizations through various touch points, including in-person, email, and online; and Veeva Vault, a cloud enterprise content management platform and suite of applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, and quality. It has a 90.23 P/E ratio. It also provides Veeva Network master data management solutions for the management of customer master and product master data.

Since January 1, 0001, it had 0 insider buys, and 25 selling transactions for $17.37 million activity.

Ratings analysis reveals 75% of Veeva Systems’s analysts are positive. Out of 4 Wall Street analysts rating Veeva Systems, 3 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $43.0 while the high is $48.0. The stock’s average target of $44.67 is -42.50% below today’s ($77.69) share price. VEEV was included in 4 notes of analysts from August 31, 2016. The stock of Veeva Systems Inc. (NYSE:VEEV) earned “Buy” rating by Needham on Wednesday, August 31. The company was initiated on Tuesday, October 4 by Goldman Sachs. Canaccord Genuity maintained it with “Buy” rating and $48.0 target in Wednesday, November 23 report. Stifel Nicolaus maintained the shares of VEEV in report on Wednesday, August 31 with “Buy” rating.

Glynn Capital Management Llc holds 4.6% of its portfolio in Veeva Systems Inc. for 324,692 shares. Brown Capital Management Llc owns 6.00 million shares or 4.12% of their US portfolio. Moreover, White Elm Capital Llc has 3.12% invested in the company for 279,300 shares. The Missouri-based Jag Capital Management Llc has invested 2.21% in the stock. Riverbridge Partners Llc, a Minnesota-based fund reported 1.57 million shares.

The stock decreased 0.24% or $0.19 during the last trading session, reaching $77.69. About 1.03M shares traded. Veeva Systems Inc. (VEEV) has risen 114.93% since March 9, 2017 and is uptrending. It has outperformed by 98.23% the S&P500.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 11 have Buy rating, 5 Sell and 7 Hold. Therefore 48% are positive. Johnson & Johnson has $170.0 highest and $90 lowest target. $137.35’s average target is 4.01% above currents $132.06 stock price. Johnson & Johnson had 91 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Monday, February 26. The stock has “Hold” rating by Citigroup on Monday, September 25. Barclays Capital upgraded the stock to “Overweight” rating in Tuesday, December 1 report. The rating was maintained by Piper Jaffray on Tuesday, July 18 with “Hold”. As per Friday, July 21, the company rating was downgraded by BTIG Research. The stock has “Outperform” rating by Cowen & Co on Tuesday, August 25. BMO Capital Markets maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, October 5. BMO Capital Markets has “Buy” rating and $145.0 target. The firm earned “Hold” rating on Wednesday, October 18 by Stifel Nicolaus. The stock has “Hold” rating by Jefferies on Tuesday, August 15. The stock has “Buy” rating by Wells Fargo on Friday, January 12.

Investors sentiment increased to 0.87 in Q3 2017. Its up 0.04, from 0.83 in 2017Q2. It is positive, as 45 investors sold JNJ shares while 871 reduced holdings. 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Burt Wealth Advisors holds 12,158 shares. Thomas Story Son Limited Liability Company owns 95,263 shares for 6.68% of their portfolio. Boys Arnold And Incorporated holds 1.76% or 85,160 shares in its portfolio. Gilman Hill Asset Limited holds 0.67% or 12,601 shares. 51,109 are held by Excalibur Mngmt Corporation. 870 are held by Mitsubishi Ufj Secs Limited. Cue Grp, Arizona-based fund reported 13,125 shares. Northwestern Mutual Wealth Management Communication has invested 0.41% in Johnson & Johnson (NYSE:JNJ). Ohio-based Shoker Invest Counsel has invested 1.9% in Johnson & Johnson (NYSE:JNJ). Ssi Investment Management owns 8,655 shares for 0.1% of their portfolio. Marshall Wace Llp holds 15,650 shares. Connecticut-based Pettee Invsts has invested 12.18% in Johnson & Johnson (NYSE:JNJ). Healthcor Mgmt LP holds 683,050 shares or 2.98% of its portfolio. Boltwood Mgmt stated it has 13,025 shares. Grantham Mayo Van Otterloo & Ltd Limited Liability Company owns 4.56M shares or 3.47% of their US portfolio.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on April, 17. They expect $2.01 earnings per share, up 9.84% or $0.18 from last year’s $1.83 per share. JNJ’s profit will be $5.39 billion for 16.43 P/E if the $2.01 EPS becomes a reality. After $1.74 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts 15.52% EPS growth.